FLJ22763 Inhibitors
FLJ22763 Inhibitors are chemical compounds that lead to the reduced functional activity of FLJ22763. Compounds such as Wortmannin and LY 294002 act as potent inhibitors of phosphatidylinositol 3-kinase. Inhibiting PI3K would result in a reduced activity of FLJ22763 if it is a part of this pathway. Similarly, the inhibition of mTOR by Rapamycin could suppress FLJ22763 activity if connected to mTOR signaling. Furthermore, the MAPK/ERK pathway, which is critical for cell differentiation and proliferation, can be targeted by MEK inhibitors like U0126 and PD 98059, leading to the diminished activity of FLJ22763 if it is associated with this route. Additional inhibitors such as SP600125 and SB 203580 specifically target the JNK and p38 MAP kinase pathways, respectively. If FLJ22763 is implicated in stress response or inflammation processes governed by JNK or is linked to the p38 MAPK pathway, these inhibitors would effectively decrease FLJ22763 activity.
In addition to kinase inhibitors, proteasome and Aurora kinase inhibitors play a role in diminishing the functionality of FLJ22763. Bortezomib's proteasome inhibition could impact the turnover and hence the functional levels of FLJ22763 if its degradation is proteasome-dependent. Aurora kinase inhibitors, like ZM-447439, could attenuate FLJ22763 activity if it is involved in cell cycle regulation intertwined with Aurora kinase functions. Tyrosine kinase inhibitors Dasatinib and Gefitinib further broaden the scope of FLJ22763 inhibition. Dasatinib's broad spectrum of tyrosine kinase inhibition could diminish FLJ22763 activity if it is modulated by specific tyrosine kinases, while Gefitinib, by inhibiting the EGFR, would have a similar effect if FLJ22763 is an element of the EGFR signaling cascade. Collectively, these compounds provide a multifaceted approach to indirectly inhibit FLJ22763 through various cellular mechanisms and pathways, each contributing to the overall decrease in the functional activity of the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and specific inhibitor of phosphatidylinositol 3-kinase (PI3K). FLJ22763, which may be involved in PI3K/Akt signaling, would have diminished functional activity due to the inhibition of PI3K, leading to reduced phosphorylation and activation of downstream targets. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, which can indirectly diminish FLJ22763 activity if FLJ22763 is regulated by phosphorylation through one or more kinases that are susceptible to staurosporine's action. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, which is a central regulator of cell growth and proliferation, rapamycin can reduce the functional activity of FLJ22763 if FLJ22763 is involved in mTOR signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is another specific inhibitor of PI3K. It would lead to a decrease in FLJ22763 activity by inhibiting PI3K and thereby reducing Akt signaling pathway activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. If FLJ22763 is involved in this pathway, U0126 would reduce its activity by preventing the activation of ERK, which may be upstream or downstream of FLJ22763. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is also an MEK inhibitor. It would cause a reduction in FLJ22763 activity by inhibiting the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress and inflammatory responses. If FLJ22763 operates within JNK signaling pathways, SP600125 would lead to diminished functional activity of FLJ22763 by inhibiting JNK activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase, which is part of the MAPK pathway. If FLJ22763 is linked to the p38 MAPK pathway, SB 203580 would decrease its activity by inhibiting p38 MAPK. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If FLJ22763 is subject to proteasomal degradation, inhibition of the proteasome by bortezomib could indirectly decrease FLJ22763 functional activity by affecting its turnover. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. If FLJ22763 is involved in cell cycle regulation and interacts with Aurora kinases, its activity could be diminished by the inhibition of these kinases. | ||||||